Morphotek Signs Collaboration Agreement With Synageva
Published: 01-Jul-2009
To develop therapeutic monoclonal antibodies for treatment of various forms of cancer and infectious disease
Morphotek has signed a research collaboration agreement with Synageva to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.
Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP) technology and its expertise to produce and develop a therapeutic monoclonal antibody.
Philip Sass, Executive Vice President and Chief Operating Officer of Morphotek, said: “We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I.”
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
White Papers
Browse A-Z
CaseBase Management
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
SafetyBase Interchange
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
ClinicalBase Trial
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
Reliable Prediction of White Plasma Levels
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Kinetics and Metabolism
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Drug Safety Evaluation
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
